News Minimalist logo

Biocon Ltd enters weight loss drug market amid expiring patents

Mint — April 8, 2024, 12:00 PM UTC

Summary: Biocon Ltd is venturing into weight loss drugs as patents for medications like Saxenda are expiring. The company's generic liraglutide injectible has UK approval, with more peptide formulations in development. The anti-obesity market, expected to reach $100 billion by 2030, is attracting companies like Biocon, Sun Pharma, Dr. Reddy's, and Cipla. Novo Nordisk plans to introduce Wegovy and Ozempic in India by 2026.

Full article

Article metrics

The article metrics are deprecated.

I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.

Timeline:

  1. [4.0]
    New weight-loss drugs may surpass Wegovy's effectiveness (Irish Medical Times)
    154d 19h
    Source
  2. [6.5]
    Weight-loss drugs like Ozempic drive $21B sales in 2023 (The Conversation)
    159d 6h

    ScoresSource
  3. [6.1]
    Ozempic weight-loss drug gaining popularity despite side effects (The Conversation)
    159d 6h

    ScoresSource
  4. [2.7]
    Semaglutides' weight loss benefits may be overestimated (New York Post )
    159d 6h
    Source
  5. [3.5]
    Ozempic may impact pregnancy despite birth control use (WFLA)
    164d 9h
    Source
  6. [5.3]
    Medicare spending on diabetes drugs increased significantly in 2022 (CNN)
    165d 1h

    ScoresSource